EU Regulators Recommend Lilly's Jaypirca for Broad CLL Approval
LLY sits 80% above its 52-week low of $623.78.
Summary
The CHMP has recommended Eli Lilly's Jaypirca for approval in the European Union for adults with Chronic Lymphocytic Leukemia (CLL) across all lines of therapy. This is a significant positive regulatory step, paving the way for full EU market access for this new oncology drug. A final decision from the European Commission is expected within one to two months. Lilly has also submitted Jaypirca for FDA approval in CLL, with a decision anticipated in the second half of 2026.
At the time of this announcement, LLY was trading at $1,124.95 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,182.73. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.